1350 related articles for article (PubMed ID: 32152478)
1. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
[TBL] [Abstract][Full Text] [Related]
2. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
3. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
[TBL] [Abstract][Full Text] [Related]
4. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.
Nistal E; Sáenz de Miera LE; Ballesteros Pomar M; Sánchez-Campos S; García-Mediavilla MV; Álvarez-Cuenllas B; Linares P; Olcoz JL; Arias-Loste MT; García-Lobo JM; Crespo J; González-Gallego J; Jorquera Plaza F
Rev Esp Enferm Dig; 2019 Apr; 111(4):275-282. PubMed ID: 30810328
[TBL] [Abstract][Full Text] [Related]
5. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
6. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
Jennison E; Byrne CD
Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
8. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Jayakumar S; Loomba R
Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
[TBL] [Abstract][Full Text] [Related]
9. Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review.
Mohammadi Z; Poustchi H; Motamed-Gorji N; Eghtesad S; Hekmatdoost A; Saniee P; Merat S
Arch Iran Med; 2020 Jan; 23(1):44-52. PubMed ID: 31910634
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
Wieland A; Frank DN; Harnke B; Bambha K
Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
12. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota and non-alcoholic fatty liver disease.
Gkolfakis P; Dimitriadis G; Triantafyllou K
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
[TBL] [Abstract][Full Text] [Related]
16. Immunonutritional contribution of gut microbiota to fatty liver disease.
Fernández-Musoles R; García Tejedor A; Laparra JM
Nutr Hosp; 2020 Feb; 37(1):193-206. PubMed ID: 31793324
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
19. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
Yang YJ; Ni YH
J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]